This review analyzed data from 2066 patients with open-angle glaucoma or ocular hypertension. The researchers compared a fixed-dose combination of tafluprost and timolol against a group that switched to single-drug monotherapy. The goal was to see how well each approach lowered intraocular pressure and how safe the treatments were.
The combination therapy produced a larger average drop in eye pressure compared to the monotherapy switch. Patients taking the combination saw a greater reduction in pressure than those who switched to single medications. This difference was consistent across the pooled data and in specific groups like treatment-naive individuals.
Safety data showed that 16 percent of patients experienced any adverse event, while serious adverse events occurred in 2 percent of cases. Only 2 percent of patients discontinued the treatment. The review noted minimal systemic side effects and a satisfactory safety profile. The authors endorse the clinical application of this combination for managing these eye conditions.